AtriCure, Inc. (NASDAQ:ATRC) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET

Company Participants

Marissa Bych - Gilmartin Group, Investor Relations

Michael Carrel - President and Chief Executive Officer

Angela Wirick - Chief Financial Officer

Conference Call Participants

Robbie Marcus - J.P. Morgan

Bill Plovanic - Canaccord

Marie Thibault - BTIG

Mike Matson - Needham

Suraj Kalia - Oppenheimer

Rick Wise - Stifel

Operator

Good afternoon, and welcome to AtriCure's Q4 2022 Earnings Conference Call. My name is Amy, and I will be your coordinator for the call today. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Marissa Bych from the Gilmartin Group for the few introductory comments.

Marissa Bych

Great. Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call (513) 644-4484 to have one e-mail to you.

Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, including the adoption of Hybrid AF therapy and future product approvals, clearances, reimbursement and clinical trial outcomes. AtriCure's results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statements.

Additionally, we refer to non-GAAP financial measures, specifically revenue reported on a constant currency basis, adjusted EBITDA and adjusted loss per share. Reconciliation of these non-GAAP financial measures with the most directly comparable GAAP measures is included in our press release, which is available on our website.

And with that, I would like to turn the call over to Mike Carrel, President and Chief Executive Officer. Mike?

Michael Carrel

Great. Thanks and good afternoon, and thank you for joining us today. 2022 was an outstanding year for AtriCure. We executed our plan to accelerate revenue, delivering 20%-plus growth as we increased adoption across our portfolio of solutions for the treatment of atrial fibrillation, appendage management and postoperative pain management. We also drove leverage as a result of our strong topline performance and the expanding scale of our platform, while making strategic investments to drive future growth. I am incredibly proud of our team whose hard work underscores our performance and whose commitment to our mission of improving patient lives led to an impact of over 100,000 patients around the globe in 2022 alone.